Does Highmark Cover Mounjaro?

No. Highmark does not cover Mounjaro for weight loss under any line of business. Mounjaro is FDA-approved for type 2 diabetes only. Off-label weight-loss requests are denied. For weight loss, the same active ingredient (tirzepatide) is sold as Zepbound, which is FDA-approved for chronic weight management and has its own, often-excluded, coverage. Pennsylvania Medicaid dropped adult weight-loss GLP-1 coverage in 2025.

Coverage varies by specific Highmark plan — many commercial plans include a weight-management drug benefit that covers Zepbound with prior authorization, typically requiring a BMI threshold or weight-related comorbidity, while others exclude anti-obesity medications entirely. Highmark does not apply one universal Zepbound policy across all plans and markets. Check your specific plan's drug formulary or call member services to confirm whether weight-loss coverage is included and what the PA criteria require.

As with Zepbound, Wegovy coverage depends on whether your specific Highmark plan includes a weight-management drug benefit — it is not covered universally. Commercially insured members should check their plan's drug list for a Wegovy entry and prior-authorization criteria such as BMI thresholds. Pennsylvania Medicaid does not cover weight-loss GLP-1s after the 2025 policy change. Medicare members may qualify for the 2026 GLP-1 Bridge for reduced-copay weight-loss coverage.

Yes, generally for its FDA-approved use — Ozempic (semaglutide) is approved for type 2 diabetes, and Highmark covers it for that diagnosis with prior authorization, similar to Mounjaro's PA process. Ozempic is not covered for weight loss alone under most Highmark plans; that off-label use requires the weight-management benefit and the weight-loss-approved version, Wegovy, instead. Verify your specific plan's formulary for exact criteria.

Highmark publishes its drug formulary on its member website, typically under 'Pharmacy' or 'Find a Drug' — log in to your Highmark member portal or visit highmarkbcbs.com and search by your specific plan name, since formularies differ by plan type (commercial, Medicare, Medicaid) and state. You can also call Highmark member services and ask them to confirm Mounjaro, Wegovy, or Zepbound's current tier and PA status directly over the phone.

Yes, for type 2 diabetes. Pennsylvania Medicaid dropped adult weight-loss GLP-1 coverage in 2025 — but T2D coverage for Mounjaro with prior authorization continues. If you are on a Highmark Medicaid plan in Pennsylvania, Mounjaro is covered for a confirmed diabetes diagnosis. Weight-loss use is excluded. Verify on your specific Highmark Medicaid plan or call member services.

Highmark requires a confirmed type 2 diabetes diagnosis (ICD-10 E11.x), A1c of 6.5% or greater, and documented trial or failure of metformin (and often one additional agent). Patient must be 18 or older. Quantity limit is typically 4 pens per 28 days. Your prescriber submits the PA. Verify specific criteria on the Highmark formulary or PA policy.

No. The 2026 Medicare GLP-1 Bridge ($50/month copay, July 1, 2026 – December 31, 2027) covers weight-loss-approved products only — Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is FDA-approved for type 2 diabetes, not weight loss. Mounjaro is covered under standard Highmark Part D for diabetes only, subject to the $2,100 annual OOP cap.

Only on a Highmark commercial (employer-sponsored or individual) plan, not Medicare or Medicaid. Commercially insured members with Mounjaro coverage may pay as little as $25/month; without coverage, cash price applies, up to 13 fills, expiring 12/31/2026. The card is not available to Highmark Medicare Part D, Medicare Advantage, Medicaid, Medigap, DoD, VA, or TRICARE beneficiaries.